Phase 2
N=201
Expanding Use of CGM in Critical Care: Impact on Nurse Work Patterns and Patient Outcomes
Hyperglycemia
Bottom Line
View on ClinicalTrials.gov: NCT05571397 ↗Enrolled (actual)
201
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcome: Primary: Percentage of Time in Target Glycemic Ranges — 76; 65; 69; 61 percentage of time in target ranges — p=<0.001
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Dexcom G6 (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Ohio State University
- Primary completion
- Sep 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Time in Target Glycemic Ranges |
76; 65; 69; 61; 37; 30 | <0.001 sig |
| SECONDARY Percent of Time in Hypoglycemic Ranges |
0.41; 0.19; 0.06; 0.08 | — |
Summary
The primary objective of this implementation study is to assess the feasibility of real time continuous glucose monitoring (CGM) implementation using a CGM plus (+) point-of-care (POC) protocol among patients on IV insulin or those with hyperglycemia (>250mg/dl) in the critical care hospital environments.
Eligibility Criteria
Inclusion Criteria
- adults >18 years old,
- admitted to Ohio State University Wexner Medical Center MICU and
- have hyperglycemia (glucose >250mg/dl) or are currently on IV insulin.
Exclusion Criteria
- Current COVID-19 infection,
- Refractory shock (Levophed dose >0.5 mcg/kg/min or equivalent)
- Actively being treated for diabetic ketoacidosis (DKA)
- Actively being treated for hyperosmolar non-ketoacidosis (HONK)
- Pitting edema, anasarca, blue or purple discoloration to left upper extremity
- Treated with high dose acetaminophen (>1 gram Q6 hours)
- Treated with hydroxyurea
- Are pregnant, patients
- Using home insulin pump therapy during hospitalization, or
- Reside in a corrections institution.
Data sourced from ClinicalTrials.gov (NCT05571397). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.